Form 4: Akero Therapeutics CFO Acquires Shares Through Employee Stock Purchase Plan

Akero Therapeutics' Chief Financial Officer, William Richard White, acquired 890 shares of common stock at a discounted price through the company's Employee Stock Purchase Plan.

Summary

• William Richard White, Chief Financial Officer of Akero Therapeutics, Inc. (AKRO), acquired 890 shares of common stock.
• The transaction occurred on June 30, 2025.
• Shares were purchased at a price of $23.868 per share.
• The acquisition was made pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan (ESPP).
• The purchase price represents 85% of the closing price of the Issuer's common stock on January 2, 2025.
• Following this transaction, Mr. White beneficially owns 58,411 shares of common stock.
• The transaction is exempt under Rule 16b-3(c) and Rule 16b-3(d).

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive, the Chief Financial Officer, through an Employee Stock Purchase Plan is generally viewed positively as it indicates continued confidence in the company's prospects and aligns management's interests with shareholders. The transaction itself is routine and expected for participants in such plans.

Positives

• Chief Financial Officer William Richard White increased his direct ownership in Akero Therapeutics, Inc. by acquiring 890 shares.
• The acquisition was made through the company's Employee Stock Purchase Plan, indicating participation in employee benefit programs.
• The purchase price of $23.868 per share, representing 85% of the January 2, 2025 closing price, suggests a favorable acquisition cost for the insider.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction under an Employee Stock Purchase Plan, which is a common benefit offered by publicly traded companies across various industries, including biotechnology. Such plans encourage employee ownership and align employee interests with shareholder value.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are standard compensation tools in many industries, including biotech, allowing employees to purchase company stock, often at a discount. The 15% discount (85% of closing price) is a common feature of such plans, aligning with typical industry practices for ESPPs.

Related Party Transactions

• The acquisition of shares by William Richard White, Chief Financial Officer, was conducted through the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, which is a pre-approved arrangement between the company and its employees.

Stakeholder Impact

• Shareholders: Increased insider ownership may signal confidence, potentially viewed positively.
• Employees: Reinforces the existence and utilization of employee benefit programs like the ESPP.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Trading, Stock Purchase, Employee Stock Purchase Plan, CFO, William Richard White, Equity Acquisition